Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
NCT00000358 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2017-01-12
Summary
The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.
Conditions
- Opioid-Related Disorders
- Substance-Related Disorders
Interventions
- DRUG
-
Lofexidine
Sponsors & Collaborators
- collaborator OTHER
-
National Institute on Drug Abuse (NIDA)
lead NIH
Principal Investigators
-
Charles O'Brien, M.D., Ph.D. · PDVAMC Treatment Research Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 21 Years
- Max Age
- 59 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Lofexidine for Inpatient Opiate Detox
NCT00235729 ·Status: COMPLETED ·Phase: PHASE3
-
Lofexidine for Opiate Withdrawal - 1
NCT00032942 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1
NCT00142909 ·Status: COMPLETED ·Phase: PHASE2
-
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
NCT04056182 ·Status: COMPLETED ·Phase: PHASE2
-
Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
NCT01650649 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients
NCT01820442 ·Status: COMPLETED ·Phase: PHASE1
-
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
NCT05712707 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
NCT04070157 ·Status: TERMINATED ·Phase: PHASE2
-
Lofexidine for Inpatient Opiate Detox in Singapore
NCT01675648 ·Status: COMPLETED ·Phase: PHASE4
-
Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal
NCT04218240 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects
NCT02391571 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacodynamic Evaluation of Intranasal Nalmefene
NCT04828005 ·Status: COMPLETED ·Phase: PHASE1
-
Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists
NCT05338632 ·Status: RECRUITING ·Phase: PHASE1
-
Buprenorphine Maintenance for Opiate Dependence - 6
NCT00000357 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Cannabidiol for Opioid Withdrawal
NCT04238754 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
NCT04470050 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
NCT00000355 ·Status: COMPLETED ·Phase: PHASE1
-
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
NCT00134888 ·Status: COMPLETED ·Phase: NA
-
Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
NCT00000353 ·Status: COMPLETED ·Phase: PHASE2
-
User Acceptability of a Device-Based Opioid Overdose Intervention
NCT04530591 ·Status: COMPLETED
-
Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site
NCT00781898 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Assessment of Fentanyl Dose Requirements in Opioid-maintained Individuals
NCT01358500 ·Status: UNKNOWN ·Phase: NA
-
Aprepitant Effects on Oxycodone Response
NCT00999544 ·Status: COMPLETED ·Phase: NA
-
Neurobiology of Opioid Dependence: 2 - 2
NCT00000193 ·Status: WITHDRAWN ·Phase: PHASE2
-
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
NCT05053503 ·Status: COMPLETED ·Phase: NA